There are probably fewer than a dozen specialist Gaucher's disease treatment centers in the whole of Europe, and so it seems curious at first that Oxford GlycoSciences PLC (OGS) would need a European partner, Switzerland's Actelion Pharmaceuticals Ltd., for help in marketing oral miglustat (Zavesca, formerly known as Vevesca), its treatment for the lysosomal storage disorder [See Deal].
But Actelion's experience marketing bosentan (Tracleer) worldwide for pulmonary arterial hypertension, and its expertise and established infrastructure in post-approval patient...